CRVS—(+82%/PM)—climbs on the COVID-19 bandwagon: http://www.globenewswire.com/news-release/2020/07/07/2058456/0/en/Corvus-Pharmaceuticals-Initiates-Clinical-Trial-of-Novel-Immunotherapy-for-Patients-with-COVID-19.html